Primary Biliary Cholangitis News and Research

RSS

Bile acids reduce desire for cocaine, finds study

Bile acids -- gut compounds that aid in the digestion of dietary fats -- reduce the desire for cocaine, according to a new study by researchers at Vanderbilt University Medical Center and the University of Alabama at Birmingham.

31 Aug 2018

Antidepressant drug appears to effectively stop progression of PBC

Gail Wright considered herself healthy. She had no idea she had a chronic liver disease. "I was at a routine check-up and my doctor said my liver enzymes were elevated. I was sent to a specialist but I wasn't too worried. I didn't have any symptoms."

27 Jun 2018

Research shows that treating cholestasis in father lowers risk of high blood pressure in son

New research led by Professor Catherine Williamson, School of Life Course Sciences, shows that using drugs to treat male mice with cholestasis reduced the likelihood of male offspring developing high blood pressure.

11 Jun 2018

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.

13 Apr 2018

Newcastle scientists develop promising new test to identify patients with rare liver disease

Newcastle scientists and medics have developed a promising new test to identify patients with a rare liver disease who will not respond to standard treatment, allowing earlier intervention with alternatives.

2 Dec 2016

Over-the-counter and prescription pain medications linked to drug-induced liver injury

More than 1,000 medications, with acetaminophen being the most common, have been associated with drug-induced liver injury.

30 Nov 2016

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.

1 Jun 2016